Daiichi Sankyo | Sustainability Performance
Engages in the research, development, and marketing of pharmaceutical products.
2007
Japan
10,001+ employees
Pharmaceuticals
$10B+ in revenue
$1B - 10B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#9073
Overallⓘ#461
in Japanⓘ#220
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsCarbon certificatesEnergy consumptionWaste ManagementWater ManagementAir & land impactNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Laggard
Aligned
Aligned
Critical
Laggard
Intensity
Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Waste generation intensity (tonnes /$M)
Industry Benchmark
14.2
B/M 22.4
309.3
B/M 312.2
51.0
B/M 42.0
0.9
B/M 0.4
Powered by illuminem and GIST Impact
Controversy level
- Daiichi Sankyo faced multiple US product liability lawsuits over its Benicar hypertension drug (paying USD 300 million 2017 settlement) plus the disastrous 2008 USD 4.6 billion Ranbaxy acquisition and subsequent FDA exclusion.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
7-10
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.